-
IntroducedJan 05, 2023
-
Passed House
-
Passed Senate
-
Signed into Law
Title: relative to affordability and safety of clinician administered drugs.
Last Action See all actions
House • Oct 17, 2024: Interim Study Report: Not Recommended for Future Legislation (Vote 16-0)
Latest Bill Text See all bill texts
Official Summary/Bill Text
Comments on HB 513
Tweets
Whip Lists
Sponsors
Votes
Actions
- Oct 17, 2024 | House
- Executive Session: 10/17/2024 10:00 am LOB 302-304
- Interim Study Report: Not Recommended for Future Legislation (Vote 16-0)
- Sep 12, 2024 | House
- Full Committee Work Session: 09/12/2024 10:00 am LOB 302-304
- Jan 03, 2024 | House
- Refer for Interim Study: MA VV 01/03/2024 HJ 1 P. 36
- Nov 08, 2023 | House
- Committee Report: Refer for Interim Study 11/08/2023 (Vote 19-0; CC) HC 49 P. 5
- Nov 15, 2023 | House
- ==CANCELLED== Executive Session: 11/15/2023 11:00 am LOB 302-304 HC 42
- Nov 08, 2023 | House
- ==RECESSED== Executive Session: 11/08/2023 01:30 pm LOB 302-304 HC 42
- Sep 20, 2023 | House
- ==RESCHEDULED== Subcommittee Work Session: 09/20/2023 01:15 pm LOB 302-304 HC 36
- Sep 06, 2023 | House
- ==CANCELLED== Subcommittee Work Session: 09/06/2023 01:15 pm LOB 302-304
- Mar 15, 2023 | House
- Executive Session: 03/15/2023 11:00 am LOB 302-304
- Subcommittee Work Session: 03/15/2023 10:05 am LOB 302-304
- Retained in Committee
- Mar 08, 2023 | House
- Subcommittee Work Session: 03/08/2023 10:00 am LOB 302-304
- Executive Session: 03/08/2023 01:15 pm LOB 302-304
- Feb 15, 2023 | House
- Public Hearing: 02/15/2023 02:00 pm LOB 302-304
- Feb 07, 2023 | House
- ==CANCELLED== Public Hearing: 02/07/2023 02:15 pm LOB 210-211
- Jan 05, 2023 | House
- Introduced (in recess of) 01/05/2023 and referred to Commerce and Consumer Affairs HJ 3 P. 19
Bill Texts
Documents